Seguir
Sam Wilks
Sam Wilks
Dirección de correo verificada de cam.ac.uk
Título
Citado por
Citado por
Año
Antibody landscapes after influenza virus infection or vaccination
JM Fonville, SH Wilks, SL James, A Fox, M Ventresca, M Aban, L Xue, ...
Science 346 (6212), 996-1000, 2014
4422014
Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands
R Bodewes, G de Mutsert, FRM Van Der Klis, M Ventresca, S Wilks, ...
Clinical and Vaccine Immunology 18 (3), 469-476, 2011
1742011
Defining the risk of SARS-CoV-2 variants on immune protection
MM DeGrace, E Ghedin, MB Frieman, F Krammer, A Grifoni, A Alisoltani, ...
Nature 605 (7911), 640-652, 2022
1352022
A review of influenza haemagglutinin receptor binding as it relates to pandemic properties
S Wilks, M de Graaf, DJ Smith, DF Burke
Vaccine 30 (29), 4369-4376, 2012
912012
Mapping SARS-CoV-2 antigenic relationships and serological responses
SH Wilks, B Mühlemann, X Shen, S Türeli, EB LeGresley, A Netzl, ...
Science 382 (6666), eadj0070, 2023
712023
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
B Ying, B Whitener, LA VanBlargan, AO Hassan, S Shrihari, CY Liang, ...
Science translational medicine 14 (630), eabm3302, 2021
662021
Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant
DL Gordon, D Sajkov, Y Honda-Okubo, SH Wilks, M Aban, IG Barr, ...
Vaccine 34 (33), 3780-3786, 2016
612016
BA. 2 and BA. 5 omicron differ immunologically from both BA. 1 omicron and pre-omicron variants
A Rössler, A Netzl, L Knabl, H Schäfer, SH Wilks, D Bante, ...
Nature communications 13 (1), 7701, 2022
532022
Antigenic maps of influenza A (H3N2) produced with human antisera obtained after primary infection
JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ...
The Journal of infectious diseases 213 (1), 31-38, 2016
382016
SARS-CoV-2 variant vaccine boosters trial: preliminary analyses
AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ...
MedRxiv, 2022.07. 12.22277336, 2022
342022
Influenza virus infection history shapes antibody responses to influenza vaccination
M Auladell, HVM Phuong, LTQ Mai, YY Tseng, L Carolan, S Wilks, ...
Nature medicine 28 (2), 363-372, 2022
342022
Analysis of SARS-CoV-2 omicron neutralization data up to 2021-12-22
A Netzl, S Tureli, E LeGresley, B Mühlemann, SH Wilks, DJ Smith
BioRxiv, 2021.12. 31.474032, 2022
222022
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial
AR Branche, NG Rouphael, DJ Diemert, AR Falsey, C Losada, LR Baden, ...
Nature medicine 29 (9), 2334-2346, 2023
122023
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
A Rössler, A Netzl, L Knabl, D Bante, SH Wilks, W Borena, D Von Laer, ...
Nature Communications 14 (1), 5224, 2023
122023
Bivalent and monovalent SARS-CoV-2 variant vaccine boosters improve coverage of the known antigenic landscape: results of the COVID-19 variant immunologic landscape (COVAIL) trial
A Branche, N Rouphael, D Diemert, A Falsey, C Losada, LR Baden, ...
Research Square, 2023
32023
Influenza virus infection history drives and shapes antibody responses to influenza vaccination
A Fox, M Auladell, H Phuong, MQ Le, YY Tseng, L Carolan, S Wilks, ...
12021
Visualisation and analysis of patterns in serological data using" antibody landscapes"
SH Wilks
12018
Antigenic maps of influenza A/H3N2 virus produced with human antisera obtained after primary infection
JM Fonville, PLA Fraaij, G de Mutsert, SH Wilks, R van Beek, ...
J Infect Dis, 2015
12015
Characterization of A/H7 influenza virus global antigenic diversity and key determinants in the hemagglutinin globular head mediating A/H7N9 antigenic evolution
A Kok, R Scheuer, TM Bestebroer, DF Burke, SH Wilks, MI Spronken, ...
Mbio 14 (5), e00488-23, 2023
2023
Mapping SARS-CoV-2 antigenic relationships and serological responses
D Smith, S Wilks, S Tureli, A Netzl, E Legresley
2023
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20